My watch list  

Drug Development

Companies Drug Development

Pantherna Therapeutics GmbH, Germany

Pantherna Therapeutics is a privately-held biopharmaceutical Company developing first-in-class therapeutics for vascular diseases. Pantherna’s innovative technology platform is based on advanced nanoparticles for the delivery and expression of therapeutic mRNA drugs in the endothelium. Pantherna is more

Rigontec GmbH, Germany

Rigontec is a leader in the field of RIG-I-activating RNA therapeutics. Using our proprietary RIG-I agonist platform, we are taking advantage of one of the most important pathways of the innate immune system to develop a novel approach to cancer immunotherapy. Rigontec's proprietary agonists specifi more

Inflamalps SA, Switzerland

Inflamalps is a biopharmaceutical company established in Valais, Switzerland Our mission is ‘’to discover and develop novel medicines to treat inflammation with a focus on chronic inflammatory diseases of the eye and of the skin” Our team comprises experienced pharmaceutical industry and biotechnolo more

News Drug Development

  • Novel materials convert visible into infrared light

    Columbia University scientists, in collaboration with researchers from Harvard, have succeeded in developing a chemical process to convert visible light into infrared energy, allowing innocuous radiation to penetrate living tissue and other materials without the damage caused by high-intensity light more

  • Leukemia Epigenetics in Focus

    Some severe forms of leukemia develop because proteins on the epigenetic level lose their regulative function. Now, in a broad international collaboration, UK researchers have identified molecules that can effectively inhibit the dysregulated proteins. In the journal Angewandte Chemie, researchers r more

  • Clues to making drugs for "undruggable" targets

    Nicolas Thomä's group at the FMI has joined forces with the group of Benjamin Ebert at Harvard’s Broad Institute to show how thalidomide analogs mediate degradation of many more proteins than previously anticipated. These proteins – zinc finger transcription factors – play a role in cancer and devel more

All news on drug development

White papers Drug Development

All white papers on drug development

Events Drug Development


Characterization of AD Animal Models: Building In Vivo Tools to Assess Next-Generation AD Therapeutics

                        Preclinical development of drug candidates for Alzheimer’s disease (AD) takes multiple different paths; animal models are indispensable tools to support diverse preclinical drug development programs. Charles River performs in-house evaluations employing several mouse models


Trends, Trials and Triumphs in In Vitro Toxicology

                        In vitro alternatives for toxicology screening and animal testing are increasing in variety. While validation against animal tests is costly and may result in false rejection, human clinical and/or mechanistic data is revolutionizing our acceptance and understanding of these


Nonclinical and Clinical Bioanalytical Assay Requirements for Biosimilar Drug Development

An important aspect of planning any biosimilar drug development program is the development and validation of robust bioanalytical assays to accompany nonclinical and clinical studies. Although many of these assays are not unique to biosimilar programs and follow regulatory guidelines in their respec

Publications Drug Development

All publications on drug development

Market studies Drug Development

All market studies on drug development

Drug development

Drug development Drug development or preclinical development is defined in many pharmaceutical companies as the process of taking a new chemical lead through the stages necessary to allow it to be tested in human clinical trial s, although a broa ... more


This is where you can add this topic to your personal favourites

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE